Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

MIXED(2)

DRUG(1)

Binimetinib

1 trial

phase_1

university-health-network-toronto

Pembrolizumab

1 trial

phase_1

university-health-network-toronto

Crizotinib

1 trial

phase_2

university-health-network-toronto

3 unique interventions2 categories

Analytics

Trial Phases

Phase 11

Phase 21

Trial Status

Completed1

Other1

Role Distribution

Principal Investigator2

PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT04084717Phase 2Completed

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

MET Activating MutationMET AmplificationNon-squamous Non-small-cell Lung Cancer+2 more

PrincipalinvestigatorStart date: 2019-12-03

NCT03991819Phase 1Active Not Recruiting

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Non-small Cell Carcinoma

PrincipalinvestigatorStart date: 2019-09-20

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

MET Activating Mutation1 MET Amplification1 Non-small Cell Carcinoma1 Non-squamous Non-small-cell Lung Cancer1 ROS1 Gene Rearrangement1 Stage IV Non-small Cell Lung Cancer1

Affiliations

Princess Margaret Cancer Centre

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ido Wolf, MD

Tel-Aviv Sourasky Medical Center

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Antony Magliocco, MD

Protean BioDiagnostics

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Eugenie Younger, MD

Gloucestershire Hospitals NHS Foundation Trust

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Andreas Polychronis, MD

Mount Vernon Cancer Centre

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Adam Berger, MD

Rutgers Cancer Institute

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Astrid Ammendola, MD

Asklepios Klinik Gauting GmbH

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Igor Puzanov, MD

Roswell Park

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Louise Medley, MD

Torbay and South Devon NHS foundation

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

Andrew Conn, MD

Bradford Teaching Hospitals

1 trials

Shared therapeutic areas:

Stage IV Non-small Cell Lung Cancer

Similarity Score5%

You Lu, MD

West China Hospital

18 trials

Shared therapeutic areas:

Non-squamous Non-small-cell Lung Cancer

Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT04084717Phase 2PrincipalInvestigator

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

MET Activating MutationMET AmplificationNon-squamous Non-small-cell Lung Cancer+2 more

Completed

NCT03991819Phase 1PrincipalInvestigator

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Non-small Cell Carcinoma

Active Not Recruiting

All 2 trials loaded